| Read Time: < 1 minute

November 2015 — The defendants argued that the plaintiffs in the MDL had no claim to a “failure to warn” incretin lawsuit, citing the FDA’s approval of the drugs’ labels. In ruling on the summary judgment motion, the trial judge agreed with the defendants and dismissed 749 pending cases on preemption grounds.

Reference: Battaglia, Anthony J. “In Re Incretin Mimetics Prods. Liab. Litig.” Legal Research Tools from Casetext, 13 May 2014, casetext.com/case/in-re-incretin-mimetics-prods-liab-litig-3.

Author Photo

Gayle Gerling Pettinga

Born and raised in Evansville, Gayle is a respected, experienced lawyer and a valued community leader. She graduated near the top of her class at Indiana University’s prestigious Maurer School of Law. She’s practiced law with one of the largest firms in Indianapolis as well as one of the largest pharmaceutical companies in the world. And that means she knows how big law firms and big companies think and how they operate – and she will put that knowledge to work for you.

Gayle has received numerous awards and honors including Martindale-Hubbell — Peer Review Rated: AV®, American Institute of Personal Injury Attorneys 10 Best Attorneys in Indiana for Exceptional and Outstanding Client Service, and YWCA Evansville 100 Years, 100 Women Honoree, 2011.

Rate this Post

1 Star2 Stars3 Stars4 Stars5 Stars